Scaling up national networks for imaging that supports increased dementia management

As newly approved donanemab and lecanemab hit the market for Australian patients, NIF acknowledges the urgently rising need for advanced imaging to support the provision of new dementia therapies.

These two drugs are the first disease-modifying treatments for early-stage Alzheimer’s disease approved for use in Australia – but require extensive imaging for diagnosis, monitoring (disease progression and side effects) – and the associated specialist infrastructure and experts.

Imaging is also essential to continue and accelerate dementia research, gather patient data, test new dementia treatments and improve patient outcomes into the future. These needs are also complicated by regional access.

NIF continues to play an integral part in supporting this work into dementia research and treatment, and helping to develop new therapies to improve quality of life and reduce the burden on Australians and the healthcare system.

Our national network aims to deliver imaging at increased capacity, for all Australians equitably.

 

Image courtesy of The Australian article referred to.